177Lu-PSMA-617靶向放射性配体治疗的安全性:RESIST-PC二期试验结果
RESIST-PC是一项前瞻性多中心二期试验,评估177Lu-PSMA-617在64例转移性去势抵抗性前列腺癌患者中的安全性。患者随机接受每周期6.0或7.4 GBq、每8周一次、最多4周期的治疗。最常见不良事件为口干、疲乏、恶心和腹泻,严重可能药物相关不良事件罕见,结论认为两种活度均安全耐受。
要点
- 最常见任何级别不良事件为口干(57.8%)、疲乏(53.1%)、恶心(46.9%)和腹泻(25.0%)。
- 严重可能药物相关不良事件见于5例(7.8%),无事件被认为很可能或肯定与治疗相关。
- 未观察到生命体征、心电图、肌酐或血液学参数的临床显著变化趋势。
核心结论
- 177Lu-PSMA-617以每周期6.0或7.4 GBq、每8周间隔给药安全且耐受良好,副作用易于通过标准医疗支持管理。
研究设计与样本
- RESIST-PC为前瞻性多中心二期试验(NCT03042312),计划入组200例,因申办方转移在入组71例时关闭。
- 64例(90.1%)患者接受至少1周期177Lu-PSMA-617,其中28例(36%)在6.0 GBq组、41例(64%)在7.4 GBq组。
- 患者为≥1种新型雄激素轴药物治疗后进展的转移性去势抵抗性前列腺癌,无论是否接受过化疗,要求骨髓储备充足、肾功能正常、PSMA PET显示足够PSMA表达且无PSMA阴性软组织病灶。
- 患者按1:1随机分入6.0或7.4 GBq每周期组,每8周一次,最多4周期。
- 主要安全终点通过收集不良事件并使用常见不良事件评价标准(CTCAE)分级评估。
主要发现
- 6.0 GBq组、7.4 GBq组和总体完成4周期治疗的患者分别为10例(43.5%)、19例(46.5%)和29例(45.3%)。
- 6.0 GBq组、7.4 GBq组和总体任何级别治疗中出现的不良事件(TEAE)最常见为口干(47.8%;63.4%;57.8%)、疲乏(56.5%;51.2%;53.1%)、恶心(52.2%;43.9%;46.9%)和腹泻(13.0%;31.7%;25.0%)。
- 所有其他TEAE频率在两组间相当(差异在10%以内)。
- 总体5例(7.8%)报告严重可能药物相关TEAE:1例4级硬膜下血肿、1例3级贫血、1例4级血小板减少、1例3级胃肠道出血和1例3级急性肾损伤,无事件被认为很可能或肯定与治疗相关。
关键数值与推荐
- 6.0 GBq组、7.4 GBq组和总体口干发生率分别为47.8%、63.4%和57.8%。
- 6.0 GBq组、7.4 GBq组和总体疲乏发生率分别为56.5%、51.2%和53.1%。
- 6.0 GBq组、7.4 GBq组和总体恶心发生率分别为52.2%、43.9%和46.9%。
- 6.0 GBq组、7.4 GBq组和总体腹泻发生率分别为13.0%、31.7%和25.0%。
- 总体严重可能药物相关TEAE发生率为7.8%(5例)。
临床怎么用
- 对于符合入组条件的转移性去势抵抗性前列腺癌患者,177Lu-PSMA-617每8周一次、每周期6.0或7.4 GBq、最多4周期的方案安全性可接受。
- 治疗期间口干、疲乏、恶心和腹泻常见,可通过标准医疗支持管理。
- 需监测严重但罕见的可能药物相关事件,包括硬膜下血肿、贫血、血小板减少、胃肠道出血和急性肾损伤。
局限性
- 研究因申办方转移在入组71例(计划200例)时提前关闭,样本量有限。
- 原文未报告疗效终点、剂量学分析或长期随访安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this analysis was to report the safety evaluation of 177Lu-PSMA-617 derived from the cohort of 64 patients exposed to 177Lu-PSMA-617 in the RESIST-PC trial NCT03042312 Methods: RESIST-PC was a prospective multicenter phase 2 trial. Patients with progressive metastatic castration-resistant prostate cancer after ≥ 1 novel androgen-axis drug, either chemotherapy naïve or postchemotherapy, with sufficient bone marrow reserve, normal kidney function, sufficient PSMA expression by PSMA PET, and no PSMA-negative soft-tissue lesions were eligible. Patients were randomized (1:1) into 2 activity groups (6.0 or 7.4 GBq per cycle) and received up to 4 cycles every 8 wk. The primary safety endpoint was assessed by collecting and grading adverse events using the Common Terminology Criteria for Adverse Events. Patients were followed until disease progression, death, serious or intolerable adverse events, study termination by sponsor, patient withdrawal, lost to follow-up, or 24 mo after the first cycle. Results: The study was closed at enrollment of 71 of 200 planned patients because of sponsorship transfer. A total of 64 (90.1%) patients received at least 1 cycle of 177Lu-PSMA-617: 28 (36%) in arm 1 (6.0 GBq) and 41 (64%) in arm 2 (7.4 GBq). There were 10 (43.5%), 19 (46.5%), and 29 (45.3%) patients who completed 4 cycles of 177Lu-PSMA-617 in the 6.0-GBq arm, 7.4-GBq arm, and overall, respectively. The most common treatment-emergent adverse events (TEAEs) of any grade in the 6.0-GBq arm, the 7.4-GBq arm and overall, were dry mouth (47.8%; 63.4%; 57.8%, respectively), fatigue (56.5%; 51.2%; 53.1%, respectively), nausea (52.2%; 43.9%; 46.9%, respectively), and diarrhea (13.0%; 31.7%; 25.0%, respectively). Frequencies of all other TEAEs were comparable among the 2 groups (within 10% difference). Serious possibly drug-related TEAEs were reported for 5 (7.8%) patients overall (none were considered as probably or definitely related to treatment): 1 subdural hematoma grade 4, 1 anemia grade 3, 1 thrombocytopenia grade 4, 1 gastrointestinal hemorrhage grade 3, and 1 acute kidney injury grade 3. There were no clinically significant changes in vital signs in electrocardiograms in the 2 treatment groups. No trend to creatinine increase or increasing frequency of shifts from normal to abnormal over time for any hematologic parameter was noted. Conclusion:177Lu-PSMA-617 was safe and well-tolerated at 6.0 and 7.4 GBq per cycle given at 8-wk intervals with side effects easily managed with standard medical support. With established safety, further clinical trials applying individualized dosimetry and testing different 177Lu-PSMA-617 administration schemes (activity levels, time intervals) are needed to optimize tumor dose delivery and treatment efficacy.
引用
- Calais J, Czernin J, Thin P, et al. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). J Nucl Med. 2021. PMID: 34272322. doi:10.2967/jnumed.121.262543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。